<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05093790</url>
  </required_header>
  <id_info>
    <org_study_id>CV006-037</org_study_id>
    <secondary_id>2020-005209-18</secondary_id>
    <nct_id>NCT05093790</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants</brief_title>
  <official_title>A Phase 2a Single Dose Study to Evaluate the Effect of BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in an Ex Vivo Thrombosis Chamber Model in Patients With Stable Coronary Artery Disease and Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effectiveness, safety and tolerability of&#xD;
      BMS-986141 added on to aspirin or ticagrelor or the combination on thrombus formation in both&#xD;
      healthy participants and participants with stable coronary artery disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 18, 2021</start_date>
  <completion_date type="Anticipated">March 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in thrombus area in participants receiving post-treatment BMS-986141</measure>
    <time_frame>Up to 2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinical laboratory abnormalities</measure>
    <time_frame>Up to 1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with vital sign abnormalities</measure>
    <time_frame>Up to 2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with electrocardiogram (ECG) abnormalities</measure>
    <time_frame>Up to 1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Treatment Arm 1: Ticagrelor + BMS-986141</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 2: Aspirin + BMS-986141</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 3: Ticagrelor + Aspirin + BMS-986141</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 4: BMS-986141</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Treatment Arm 1: Ticagrelor + BMS-986141</arm_group_label>
    <arm_group_label>Treatment Arm 3: Ticagrelor + Aspirin + BMS-986141</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986141</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Treatment Arm 1: Ticagrelor + BMS-986141</arm_group_label>
    <arm_group_label>Treatment Arm 2: Aspirin + BMS-986141</arm_group_label>
    <arm_group_label>Treatment Arm 3: Ticagrelor + Aspirin + BMS-986141</arm_group_label>
    <arm_group_label>Treatment Arm 4: BMS-986141</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Treatment Arm 2: Aspirin + BMS-986141</arm_group_label>
    <arm_group_label>Treatment Arm 3: Ticagrelor + Aspirin + BMS-986141</arm_group_label>
    <other_name>Acetylsalicylic acid (ASA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit: www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female between 18 to 75 years of age, inclusive, and body mass index (weight&#xD;
             kg/m2) between 18 and 35 kg/m2 (inclusive), and body weight 50 kg and 120 kg&#xD;
             (inclusive)&#xD;
&#xD;
          -  Judged to be generally in good health based on medical history, physical examination,&#xD;
             ECGs, vital signs and laboratory tests&#xD;
&#xD;
          -  Signed an informed consent document indicating they understand the purpose of and&#xD;
             procedures required for the experiment and are willing to participate in the&#xD;
             experiment&#xD;
&#xD;
          -  Willing/able to adhere to the visit schedule&#xD;
&#xD;
          -  For treatment arms groups with stable CAD participants (not for healthy volunteers&#xD;
             without CAD) one or more of: Prior angiographically proven CAD (&gt;50% stenosis of&#xD;
             proximal coronary artery), prior coronary revascularization (PCI or CABG), prior&#xD;
             myocardial infarction (MI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who meet any of the following criteria will be excluded from&#xD;
             participating in the experiment: Allergies or intolerance of aspirin, ticagrelor and&#xD;
             BMS-986141, requirement for dual antiplatelet therapy, requirement for anticoagulant&#xD;
             therapy&#xD;
&#xD;
          -  Acute Coronary syndrome or coronary revascularization within 3 months&#xD;
&#xD;
          -  Coagulation disorders (including any abnormal bleeding or blood dyscrasias), anemia,&#xD;
             renal or hepatic insufficiency or any others illness that the investigator considers&#xD;
             should exclude the participants/patients of that could interfere with the&#xD;
             interpretation to the results&#xD;
&#xD;
          -  Acute illness, including a common cold, within 7 days prior to visit or other&#xD;
             significant acute or chronic medical illness&#xD;
&#xD;
          -  Major or traumatic surgery within 12 weeks of screening&#xD;
&#xD;
          -  History of, a reason to believe that, a blood donor subject has a history of drug or&#xD;
             alcohol abuse within the past 5 years or has not abstained from alcohol for at least&#xD;
             24 hours prior to visit&#xD;
&#xD;
          -  Positive serum or urine pregnancy test&#xD;
&#xD;
          -  Not anatomically suitable for or unwilling to undergo venipunctures&#xD;
&#xD;
          -  Participation in a study of an investigational medicinal product within the last 4&#xD;
             weeks&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, would compromise the wellbeing&#xD;
             of the blood donor subject or the experiment or prevent the blood donor subject from&#xD;
             meeting or performing experiment requirements&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombosis</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Healthy Participants</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Brilinta</keyword>
  <keyword>BMS-986141</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

